<DOC>
	<DOCNO>NCT00444379</DOCNO>
	<brief_summary>The primary purpose study determine whether protease inhibitor-based antiretroviral regimen efficacious non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimen promote regression KS tumor burden person AIDS-related KS Africa .</brief_summary>
	<brief_title>Anti-Retrovirals Kaposi 's Sarcoma</brief_title>
	<detailed_description>With advent HIV epidemic , Kaposi 's sarcoma ( KS ) common adult cancer many part sub-Saharan Africa . In HIV-infected patient KS develop setting , initiation highly active anti-retroviral therapy ( HAART ) associate regression tumor , many case , even absence conventional chemotherapy . However , know specific antiretroviral drug regimens critical convey HAART 's anti-KS effect . In particular , know whether anti-KS effect protease inhibitor ( PI ) vitro animal model translate improve clinical outcome compare non-PI-based HAART regimens . To address , determine whether PI-based HAART regimen ( lopinavir/ritonavir plus emtricitabine/tenofovir ) superior non-nucleoside reverse transcriptase inhibitor ( NNRTI ) -based HAART regimen ( efavirenz plus emtricitabine/tenofovir ) promote regression KS tumor burden person AIDS-related KS sub-Saharan Africa . We enroll 224 patient AIDS-related KS Kampala , Uganda , randomly assign either PI-based HAART NNRTI-based HAART regimen , observe one year determine response KS therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Age 18 year old HIV1 infection No prior antiretroviral therapy duration , include prior use prevent perinatal transmission within prior six month . No prior chemotherapy radiotherapy KS Presence Kaposi 's sarcoma , document biopsy Pathology Department Mulago Hospital , least one mucocutaneous lesion ( include oral genital mucosal lesion ) , least 0.6 x 0.6 cm perpendicular diameter . Laboratory value obtain within 21 day prior randomization : absolute neutrophil count equal 1000/mm3 ; hemoglobin &gt; 9.0 g/dL ; platelet count &gt; 50,000/mm3 ; creatinine &lt; 2 time upper limit normal ( ULN ) ; aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 5 time ULN ; alkaline phosphatase total bilirubin &lt; 2 time ULN . In woman , negative urine pregnancy test within 28 day randomization randomization . If woman childbearing potential ( i.e. , yet reach menopause undergone hysterectomy , bilateral oophorectomy , tubal ligation ) , must willing use least two follow method contraception , provide study : condom ( male female ) , IUD , hormonebased therapy , e.g. , contraceptive pill , Norplant DepoProvera . Candidate currently reside within Uganda intend relocate away current geographical area residence duration study participation . Karnofsky performance score 70 Extensive degree mucocutaneous KS , would typically require chemotherapy radiotherapy . This define follow : One bulky cutaneous lesion , define least 5.0 cm great diameter across surface skin least 3 cm height One mucocutaneous lesion exhibit ulceration One oral lesion interfere swallow Suggestion pulmonary gastrointestinal visceral KS , evidence following : Abnormal chest xray within 21 day prior randomization otherwise unexplained , unless xray unchanged compare least 60 day earlier Positive occult blood stool test within 21 day prior randomization history overt bleed mouth rectum 21 day prior randomization Facial lymphedema lymphedema body region cause symptom ( e.g. , pain ) functional disability ( e.g. , less 85 % active range motion large joint ) Evidence currently active , untreated opportunistic infection malignancy ( include Kaposi 's sarcoma ) ; unexplained temperature &gt; 38.5 degree C Use drug , within prior 28 day , contraindicate take lopinavir/ritonavir efavirenz effect cytochrome P450 system . These include propafenone , astemizole , terfenadine , rifampin , rifapentine , ergot derivative , cisapride , lovastatin , simvastatin , pimozide , midazolam , triazolam . Active drug alcohol use , investigator ' opinion , would interfere study participation Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Kaposi 's sarcoma</keyword>
	<keyword>KSHV</keyword>
	<keyword>AIDS</keyword>
	<keyword>HHV-8</keyword>
	<keyword>treatment naive</keyword>
</DOC>